Optimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Apr 28, 2014          Expiration Date: Apr 28, 2015



By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.



Program Description


The recent approval of several novel treatment regimens in the frontline, maintenance, and relapsed/refractory settings has significantly transformed the treatment landscape for MM. Community hematologists/oncologists need the most current information on treatment-selection strategies based on risk stratification and molecular analyses, as well as on the role of maintenance therapy in delaying disease progression in MM.

"Optimal Sequencing of Treatments for Maximizing Outcomes in Multiple Myeloma" will provide guidance to community hematologists/oncologists on the optimal sequencing of treatment regimens in patients with MM in order to maximize clinical benefits and improve patient outcomes.

This webcourse is divided into three chapters, each approximately 15 minutes long. You are welcome to view each chapter individually; however, in order to receive CME credit, you must view all three chapters and complete the associated post-test and evaluation.

Click here to download a PDF transcript of the webcourse audio.


Faculty



SERGIO A. GIRALT, MD
Chief, Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Read Biography

DILIP L. SOLANKI, MD
Physician Partner
Texas Oncology: MDMC Cancer Centers
Dallas, TX

Read Biography


Target Audience


This activity is intended for community-based hematologists, oncologists, and other clinicians involved in the care of patients with multiple myeloma.


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Evaluate optimal sequencing of MM therapies based on risk stratification by cytogenetic and molecular analyses
  • Review treatment options for patients with newly diagnosed MM and assess maintenance therapies that can prolong survival
  • Assess therapies for the management of patients with relapsed and refractory MM

Accreditation


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding this activity, please email contact@pcme-rockpointe.com.


Disclosure Statement


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty/steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Sergio A. Giralt, MD: Consultant/Advisory Board: Bioline, Celgene, Janssen, Onyx, Sanofi, Seattle Genetics, Skyline Diagnostics, Spectrum Pharmaceuticals; Speaker: Celgene

Dilip Solanki, MD: Speaker: Bayer, Celgene, Millenium

Non-faculty Content Contributors:
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Latha Shivakumar, PhD; Blair St. Amand; Jay Katz, CCMEP; Ashley Marostica: Nothing to disclose

Jonathan L. Kaufman, MD: Consultant: Celgene, Janssen, Millennium, Novartis, Onyx; Principal Investigator: Celgene, Merck, Novartis

FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.


JOINTLY PROVIDED BY


Potomac Center for Medical Education and Rockpointe Oncology

Supported By


This activity is supported by an educational grant from Takeda Oncology.


By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.